Effects of enhanced adsorption haemofiltration versus haemoadsorption in severe, refractory septic shock with high levels of endotoxemia: the ENDoX bicentric, randomized, controlled trial.
Cytokine Removal
Endotoxin
Haemoadsorption
Haemoperfusion
Polymyxin B
Septic Shock
oXiris
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
14 Dec 2023
14 Dec 2023
Historique:
received:
29
09
2023
accepted:
06
12
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
14
12
2023
Statut:
epublish
Résumé
Endotoxin adsorption is a promising but controversial therapy in severe, refractory septic shock and conflicting results exist on the effective capacity of available devices to reduce circulating endotoxin and inflammatory cytokine levels. Multiarm, randomized, controlled trial in two Swiss intensive care units, with a 1:1:1 randomization of patients suffering severe, refractory septic shock with high levels of endotoxemia, defined as an endotoxin activity ≥ 0.6, a vasopressor dependency index ≥ 3, volume resuscitation of at least 30 ml/kg/24 h and at least single organ failure, to a haemoadsorption (Toraymyxin), an enhanced adsorption haemofiltration (oXiris) or a control intervention. Primary endpoint was the difference in endotoxin activity at 72-h post-intervention to baseline. In addition, inflammatory cytokine, vasopressor dependency index and SOFA-Score dynamics over the initial 72 h were assessed inter alia. In the 30, out of 437 screened, randomized patients (10 Standard of care, 10 oXiris, 10 Toraymyxin), endotoxin reduction at 72-h post-intervention-start did not differ among interventions (Standard of Care: 12 [1-42]%, oXiris: 21 [10-51]%, Toraymyxin: 23 [10-36]%, p = 0.82). Furthermore, no difference between groups could be observed neither for reduction of inflammatory cytokine levels (p = 0.58), nor for vasopressor weaning (p = 0.95) or reversal of organ injury (p = 0.22). In a highly endotoxemic, severe, refractory septic shock population neither the Toraymyxin adsorber nor the oXiris membrane could show a reduction in circulating endotoxin or cytokine levels over standard of care. Trial registration ClinicalTrials.gov. NCT01948778. Registered August 30, 2013. https://clinicaltrials.gov/study/NCT01948778.
Sections du résumé
BACKGROUND
BACKGROUND
Endotoxin adsorption is a promising but controversial therapy in severe, refractory septic shock and conflicting results exist on the effective capacity of available devices to reduce circulating endotoxin and inflammatory cytokine levels.
METHODS
METHODS
Multiarm, randomized, controlled trial in two Swiss intensive care units, with a 1:1:1 randomization of patients suffering severe, refractory septic shock with high levels of endotoxemia, defined as an endotoxin activity ≥ 0.6, a vasopressor dependency index ≥ 3, volume resuscitation of at least 30 ml/kg/24 h and at least single organ failure, to a haemoadsorption (Toraymyxin), an enhanced adsorption haemofiltration (oXiris) or a control intervention. Primary endpoint was the difference in endotoxin activity at 72-h post-intervention to baseline. In addition, inflammatory cytokine, vasopressor dependency index and SOFA-Score dynamics over the initial 72 h were assessed inter alia.
RESULTS
RESULTS
In the 30, out of 437 screened, randomized patients (10 Standard of care, 10 oXiris, 10 Toraymyxin), endotoxin reduction at 72-h post-intervention-start did not differ among interventions (Standard of Care: 12 [1-42]%, oXiris: 21 [10-51]%, Toraymyxin: 23 [10-36]%, p = 0.82). Furthermore, no difference between groups could be observed neither for reduction of inflammatory cytokine levels (p = 0.58), nor for vasopressor weaning (p = 0.95) or reversal of organ injury (p = 0.22).
CONCLUSIONS
CONCLUSIONS
In a highly endotoxemic, severe, refractory septic shock population neither the Toraymyxin adsorber nor the oXiris membrane could show a reduction in circulating endotoxin or cytokine levels over standard of care. Trial registration ClinicalTrials.gov. NCT01948778. Registered August 30, 2013. https://clinicaltrials.gov/study/NCT01948778.
Identifiants
pubmed: 38095800
doi: 10.1186/s13613-023-01224-8
pii: 10.1186/s13613-023-01224-8
doi:
Banques de données
ClinicalTrials.gov
['NCT01948778']
Types de publication
Journal Article
Langues
eng
Pagination
127Informations de copyright
© 2023. The Author(s).
Références
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546–54.
doi: 10.1056/NEJMoa022139
pubmed: 12700374
Cribbs SK, Martin GS. Expanding the global epidemiology of sepsis*. Crit Care Med. 2007;35(11):2646–8.
doi: 10.1097/01.CCM.0000288082.99980.90
pubmed: 18075373
Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003;7(1):108–14.
doi: 10.1046/j.1526-0968.2003.00005.x
pubmed: 12921125
Monard C, Rimmelé T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif. 2019;47:2–15.
doi: 10.1159/000499520
Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6(1):12.
doi: 10.1186/s40635-018-0177-2
pubmed: 29728790
pmcid: 5935601
Rimmelé T, Assadi A, Cattenoz M, et al. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant. 2009;24(2):421–7.
doi: 10.1093/ndt/gfn518
pubmed: 18799607
Nemoto H, Nakamoto H, Okada H, et al. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif. 2001;19(4):361–9.
doi: 10.1159/000046966
pubmed: 11574732
Vincent J-L, Laterre P-F, Cohen J, et al. A pilot-controlled study of A polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005;23(5):400–5.
doi: 10.1097/01.shk.0000159930.87737.8a
pubmed: 15834304
Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–52.
doi: 10.1001/jama.2009.856
pubmed: 19531784
Iwagami M, Yasunaga H, Noiri E, et al. Potential survival benefit of polymyxin B hemoperfusion in septic shock patients on continuous renal replacement therapy: a propensity-matched analysis. Blood Purif. 2016;42(1):9–17.
doi: 10.1159/000444474
pubmed: 26918904
Nakamura Y, Kitamura T, Kiyomi F, et al. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study. Crit Care. 2017;21(1):134.
doi: 10.1186/s13054-017-1712-3
pubmed: 28592318
pmcid: 5463489
Turani F, Barchetta R, Falco M, Busatti S, Weltert L. Continuous renal replacement therapy with the adsorbing filter oXiris in septic patients: a case series. Blood Purif. 2019;47:54–8.
doi: 10.1159/000499589
Schwindenhammer V, Girardot T, Chaulier K, et al. oXiris® use in septic shock: experience of two French centres. Blood Purif. 2019;47:29–35.
doi: 10.1159/000499510
Broman ME, Hansson F, Vincent J-L, Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE. 2019;14(8): e0220444.
doi: 10.1371/journal.pone.0220444
pubmed: 31369593
pmcid: 6675097
Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975–84.
doi: 10.1007/s00134-015-3751-z
pubmed: 25862039
pmcid: 4477725
Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455–63.
doi: 10.1001/jama.2018.14618
pubmed: 30304428
pmcid: 6233793
Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205–12.
doi: 10.1007/s00134-018-5463-7
pubmed: 30470853
pmcid: 6280819
Romaschin AD, Harris DM, Ribeiro MB, et al. A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods. 1998;212(2):169–85.
doi: 10.1016/S0022-1759(98)00003-9
pubmed: 9672205
Romaschin AD, Klein DJ, Marshall JC. Bench-to-bedside review: clinical experience with the endotoxin activity assay. Crit Care. 2012;16(6):248.
doi: 10.1186/cc11495
pubmed: 23206992
pmcid: 3672550
Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31(4):1250–6.
doi: 10.1097/01.CCM.0000050454.01978.3B
pubmed: 12682500
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, the Aw. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204.
doi: 10.1186/cc2872
pubmed: 15312219
pmcid: 522841
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.
doi: 10.1007/s00134-012-2769-8
pubmed: 23361625
pmcid: 7095153
Hilty M, Eberle B, Maggiorini M. Endotoxin activity in sepsis and septic shock. Intensive Care Med. 2012;38:S98.
Team RC. R: a language and environment for statistical computing. Team RC; 2013.
McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med. 1994;121(1):1–5.
doi: 10.7326/0003-4819-121-1-199407010-00001
pubmed: 8198341
Angus DC, Birmingham MC, Balk RA, et al. E5 Murine monoclonal antiendotoxin antibody in gram-negative sepsisA randomized controlled trial. JAMA. 2000;283(13):1723–30.
doi: 10.1001/jama.283.13.1723
pubmed: 10755499
Phillip Dellinger R, Tomayko JF, Angus DC, et al. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med. 2009;37(11):2929–38.
doi: 10.1097/CCM.0b013e3181b0266c
pubmed: 19770753
Romaschin AD, Obiezu-Forster CV, Shoji H, Klein DJ. Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif. 2017;44(3):193–7.
doi: 10.1159/000475982
pubmed: 28601867
Li Bassi G, Marti JD, Xiol EA, et al. The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe Pseudomonas aeruginosa pneumonia. Ann Intensive Care. 2016;6(1):58.
doi: 10.1186/s13613-016-0155-3
pubmed: 27378201
pmcid: 4932027
Honoré PM, Matson JR. Extracorporeal removal for sepsis: acting at the tissue level—the beginning of a new era for this treatment modality in septic shock *. Crit Care Med. 2004;32(3):896–7.
doi: 10.1097/01.CCM.0000115262.31804.46
pubmed: 15090989
Peng Z-Y, Bishop JV, Wen X-Y, et al. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model. Crit Care. 2014;18(4):R141.
doi: 10.1186/cc13969
pubmed: 24992991
pmcid: 4227131
Kawazoe Y, Sato T, Miyagawa N, et al. Mortality effects of prolonged hemoperfusion therapy using a polymyxin B-immobilized fiber column for patients with septic shock: a sub-analysis of the DESIRE trial. Blood Purif. 2018;46(4):309–14.
doi: 10.1159/000491744
pubmed: 30099437
Lee WY, Kim HJ, Kim EY. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study. Sci Rep. 2021;11(1):24132.
doi: 10.1038/s41598-021-03055-8
pubmed: 34916567
pmcid: 8677752
Banoub JH, Aneed AE, Cohen AM, Joly N. Structural investigation of bacterial lipopolysaccharides by mass spectrometry and tandem mass spectrometry. Mass Spectrom Rev. 2010;29(4):606–50.
doi: 10.1002/mas.20258
pubmed: 20589944
Matsumoto N, Takahashi G, Kojika M, et al. Interleukin-8 induces an elevation in the endotoxin activity assay (EAA) level: does the EAA truly measure the endotoxin level? J Infect Chemother. 2013;19(5):825–32.
doi: 10.1007/s10156-013-0567-z
pubmed: 23460381
Wendel Garcia PD, Hilty MP, Held U, Kleinert E-M, Maggiorini M. Cytokine adsorption in severe, refractory septic shock. Intensive Care Med. 2021;47(11):1334–6.
doi: 10.1007/s00134-021-06512-0
pubmed: 34471938
pmcid: 8409473
Garbero E, Livigni S, Ferrari F, et al. High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med. 2021;47(11):1303–11.
doi: 10.1007/s00134-021-06501-3
pubmed: 34601619
van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76(12):2520–6.
doi: 10.1182/blood.V76.12.2520.2520
pubmed: 2124934
Taylor FB Jr, Haddad PA, Hack E, et al. Two-stage response to endotoxin infusion into normal human subjects: Correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med. 2001;29(2):326–34.
doi: 10.1097/00003246-200102000-00020
pubmed: 11269245